OmniComm Introduces TrialMaster Version 5, the Mobile-Friendly EDC Solution for Clinical Trials
Fort Lauderdale, Fla., May 31, 2018 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc., a leading global provider of clinical data management technology, today announced the release of TrialMaster Version 5, the innovative, user-friendly solution for electronic data capture (EDC). TrialMaster’s ease of use for investigative sites, coupled with state-of-the-art analytical tools, means that life science companies can shorten the time to market for essential life-saving treatments.
“This is a groundbreaking day for the industry,” said Keith Howells, OmniComm’s chief technology officer. “While the costs for clinical research are climbing inexorably higher, the mechanisms for collecting the precious data have become mired in antiquated, second-rate technology. TrialMaster v5 changes all that. With the product’s ease of use, keystroke-level responsiveness and built-in mobile support, site and sponsor personnel alike will finally have a tool that they feel is on their side. I am confident that TrialMaster v5 would win an evaluation against any of the other EDC products on the market.”
TrialMaster v5 makes it easier for doctors, nurses and other medical professionals to enter and manage clinical trial data, thereby freeing up the maximum amount of time to care for patients. This innovative EDC solution offers:
- Intuitive user interface.
- Mobile-friendly technology.
- Electronic patient reported outcomes (ePRO) capability.
- Risk-based monitoring tools.
With an emphasis on a premium user experience, the new TrialMaster EDC represents a major milestone for OmniComm and is part of the company’s “Year of Innovation.” New eClinical solutions from OmniComm include Acuity Analytics, AutoEncoder, IRTMaster and the latest version of TrialOne®. OmniComm will showcase and demonstrate TrialMaster v5 and other new eClinical solutions at industry events around the globe, including Innovation Forum Europe, June 7-8 in Bonn, Germany, and at the DIA 2018 in Boston on June 24-28.
“This release has been close to three years in the making,” said Stephen Johnson, president and CEO of OmniComm. “Significant effort was put into making this the most intuitive and easy-to-use system we’ve ever released, utilizing the latest in cutting-edge technology, HTML5 design, award-winning usability experts, and feedback from a customer steering group. We’ve added features such as liquid layouts, modern controls, infinite scrolling and a host of other techniques to make the user experience the best possible. I have no doubt that this release will revolutionize the way clinical trial data is collected and processed.”
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, research organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com for more information.
Trademarks
OmniComm, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info
Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
KvanderPost@omnicomm.com
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
